JP6867302B2 - タンパク質の特徴を改善する方法 - Google Patents

タンパク質の特徴を改善する方法 Download PDF

Info

Publication number
JP6867302B2
JP6867302B2 JP2017556995A JP2017556995A JP6867302B2 JP 6867302 B2 JP6867302 B2 JP 6867302B2 JP 2017556995 A JP2017556995 A JP 2017556995A JP 2017556995 A JP2017556995 A JP 2017556995A JP 6867302 B2 JP6867302 B2 JP 6867302B2
Authority
JP
Japan
Prior art keywords
protein
library
binding
candidate
display system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017556995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517899A (ja
Inventor
ロバート ビー． デュブリッジ，
ロバート ビー． デュブリッジ，
Original Assignee
フル スペクトラム ジェネティクス， インコーポレイテッド
フル スペクトラム ジェネティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フル スペクトラム ジェネティクス， インコーポレイテッド, フル スペクトラム ジェネティクス， インコーポレイテッド filed Critical フル スペクトラム ジェネティクス， インコーポレイテッド
Publication of JP2018517899A publication Critical patent/JP2018517899A/ja
Application granted granted Critical
Publication of JP6867302B2 publication Critical patent/JP6867302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017556995A 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法 Active JP6867302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165173P 2015-05-21 2015-05-21
US62/165,173 2015-05-21
PCT/US2016/032660 WO2016187101A2 (en) 2015-05-21 2016-05-16 Method of improving characteristics of proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001276A Division JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Publications (2)

Publication Number Publication Date
JP2018517899A JP2018517899A (ja) 2018-07-05
JP6867302B2 true JP6867302B2 (ja) 2021-04-28

Family

ID=57320465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017556995A Active JP6867302B2 (ja) 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法
JP2021001276A Active JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021001276A Active JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Country Status (5)

Country Link
US (2) US10526597B2 (https=)
EP (1) EP3297661B1 (https=)
JP (2) JP6867302B2 (https=)
ES (1) ES2881683T3 (https=)
WO (1) WO2016187101A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881683T3 (es) 2015-05-21 2021-11-30 Full Spectrum Genetics Inc Procedimiento para mejorar las características de las proteínas
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
ATE384129T1 (de) * 2001-11-22 2008-02-15 Univ Keio Künstliche antikörperbibliothek mit super- repertoire
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20060160178A1 (en) * 2003-11-17 2006-07-20 Jonathan Rothberg Methods of generating antibody diversity in vitro
CA2572917C (en) 2004-07-06 2012-04-03 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
US20120077691A1 (en) 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
JP5920835B2 (ja) * 2010-12-01 2016-05-18 田辺三菱製薬株式会社 無細胞翻訳系でＦａｂを提示しうるポリヌクレオチド構築物ならびにそれを用いたＦａｂの製造方法およびスクリーニング方法
US20120258866A1 (en) 2011-04-05 2012-10-11 Full Spectrum Genetics, Inc. Multi-dimensional selection of protein mutants using high throughput sequence analysis
US10947305B2 (en) 2015-03-20 2021-03-16 Full Spectrum Genetics, Inc. Anti-TNFα binding compounds and uses thereof
ES2881683T3 (es) 2015-05-21 2021-11-30 Full Spectrum Genetics Inc Procedimiento para mejorar las características de las proteínas

Also Published As

Publication number Publication date
JP2021061852A (ja) 2021-04-22
WO2016187101A2 (en) 2016-11-24
ES2881683T3 (es) 2021-11-30
US10526597B2 (en) 2020-01-07
US11332735B2 (en) 2022-05-17
EP3297661A2 (en) 2018-03-28
EP3297661B1 (en) 2021-06-30
EP3297661A4 (en) 2018-11-21
WO2016187101A3 (en) 2017-04-20
US20200123530A1 (en) 2020-04-23
JP7109605B2 (ja) 2022-07-29
US20190078081A1 (en) 2019-03-14
JP2018517899A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
JP7109605B2 (ja) タンパク質の特徴を改善する方法
KR102290949B1 (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
US20240044047A1 (en) Radically diverse human antibody library
JP7291700B2 (ja) ｍＲＮＡディスプレイ抗体ライブラリー及び方法
EP3223014B1 (en) Method of analyzing binding interactions
KR102194203B1 (ko) 항체 나이브 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
EP4479583A1 (en) Single domain antibody libraries with maximized antibody developability characteristics
JP7337850B2 (ja) 抗体ライブラリー及びこれを用いた抗体スクリーニング方法
KR20230128290A (ko) 가변 중쇄 전용 라이브러리, 이의 제조 방법, 및 이의용도
Tiller Synthetic Antibodies
US20140235483A1 (en) Parallel determination of competitive binding and target specificity of a binding compound library by high-throughput dna sequencing

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190320

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210408

R150 Certificate of patent or registration of utility model

Ref document number: 6867302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250